Altogether, findings from preclinical studies suggest that reduced circulating BA levels may diminish FXR/TGR5-mediated anti-inflammatory protection, creating a permissive environment for vascular inflammation, plaque formation, and ultimately CAD progression. This evidence concerns the gene GPBAR1 and coronary artery disorder.